Trial Profile
A partially randomized, partially double-blind, placebo-controlled phase II non-inferiority study to evaluate the immunogenicity and safety of one and two dose of MVA-BN (Imvamune) smallpox vaccine in 18-55 year old healthy subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Smallpox vaccine (Primary)
- Indications Smallpox
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Bavarian Nordic
- 12 Nov 2022 Pooled analysis assessing immunological persistence and booster effects published in the Journal of Infectious Diseases
- 30 Nov 2007 Status change
- 27 Apr 2007 Status changed from recruiting to in progress.